Memantine Hydrochloride Capsule, Extended Release
Product Images NDC 0615-8662

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 0615-8662). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ncs Healthcare Of Ky, Llc Dba Vangard Labs, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Memantine 8662 1)

Chemical structure diagram of memantine hydrochloride showing the molecular framework with amine (NH2) and methyl (CH3) groups.*

FDA Label Image

Memantine-fig1.jpg (Memantine 8662 2)

A line graph showing the mean change in SIB score from baseline over 24 weeks of treatment. It compares Memantine Hydrochloride Extended-release Capsules 28 mg with Placebo, displaying clinical improvement and decline on the y-axis and weeks of treatment on the x-axis with error bars indicating SEM.*

FDA Label Image

Memantine-fig2.jpg (Memantine 8662 3)

A cumulative percentage of patients graph comparing Memantine Hydrochloride Extended-release Capsules 28 mg combined with AChEI versus Placebo combined with AChEI, showing SIB change from baseline on the x-axis and cumulative percentage on the y-axis. The graph depicts patient response distributions for both treatments.*

FDA Label Image

Memantine-fig3.jpg (Memantine 8662 4)

A line graph showing Mean (± SEM) CIBIC-Plus Scores over 24 weeks of treatment comparing Memantine Hydrochloride Extended-release Capsules 28 mg and placebo in patients receiving AChEI. The y-axis indicates clinical improvement and decline scores, with Memantine showing clinical improvement over time compared to placebo.*

FDA Label Image

Memantine-fig4.jpg (Memantine 8662 5)

A bar chart comparing the percentage of patients with different Clinical Global Impression of Change (CGIC) ratings for Memantine Hydrochloride Extended-release Capsules 28 mg versus placebo. The categories range from marked improvement to marked worsening, showing relative patient responses across the spectrum.*

FDA Label Image

Principal Display Panel (Memantine 8662 6)

Label for Memantine Hydrochloride Extended-Release Capsules 28 mg, showing product name, strength, and dosage form. The label includes manufacturer information for Aurobindo and packaging by Vanguard Labs, with multiple barcodes and lot number 8662. Storage instructions and a note for institutional use only are also present.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.